CAMBRIA-2Recruiting

A novel drug for adjuvant anti-hormone therapy in early-stage breast cancer (0-2)

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase III

What is this trial about?

To prevent -positive breast cancer from recurring, it is important to take medication for several years after the tumor has been removed () that suppresses the production or effects of hormones, since these hormones stimulate the growth of any remaining cancer cells. The goal of the CAMBRIA-2 study is to determine whether adjuvant therapy with the novel drug , which targets the hormone receptor on cancer cells, achieves better treatment outcomes than standard anti-hormone therapy. Women and men with hormone receptor-positive, -negative breast cancer following surgical removal of the tumor, provided the cancer carries an elevated risk of (moderate or high risk) and no metastases are present.

Detailed description

Breast cancer (mammary carcinoma) is a malignant disease of the breast gland tissue characterized by the uncontrolled proliferation of breast gland cells. Treatment of the disease depends on numerous factors, such as the patient’s overall health, the stage of the disease, the tumor growth rate ( index), the presence of detectable hormone receptors on the surface of the cancer cells (-positive, progesterone receptor-positive), and the increased presence of HER2 receptors on the cells (HER2-positive). Cancer cells often have hormone receptors, making anti-hormone therapy a core component of treatment.

Treatment is typically divided into two phases (neoadjuvant and adjuvant), unless metastases are already present. constitutes the first phase. This is followed by breast surgery. Depending on the disease’s risk profile, adjuvant therapy usually follows; in the case of HR-positive breast cancer, this involves anti-hormone therapy. One class of drugs used in standard anti-hormone therapy is , such as , , and ; another group consists of “selective estrogen receptor modulators” (SERMs), which include . Earlier studies have shown that combining anti-hormonal therapy with another active ingredient—a such as —can increase the treatment’s effectiveness.

The CAMBRIA-2 study is investigating camizestrant, a new drug in the SERM class, to assess its efficacy and safety compared to standard anti-hormonal therapy. Camizestrant can also be administered with or without abemaciclib. Patients are randomly assigned to one of the two study groups and receive either (), in which the anti-hormone therapy drug is selected by the treating physician, or, in the other group (), the new drug camizestrant. Both groups may be treated with or without the CDK 4/6 inhibitor abemaciclib.

The duration of treatment is planned for 7 years in both study arms. The total period will last up to 14 years. The medication has already been studied in smaller , where it demonstrated advantages over standard therapy. Patients know which study arm they are in.

Women and men aged 18 and older with hormone receptor-positive, HER2-negative early-stage breast cancer (stages 0–2) are eligible to participate in the study. The breast cancer must have already been treated surgically—meaning the first phase of treatment (usually chemotherapy plus surgery) must be complete—but the surgical removal of the tumor must have taken place no more than 12 months ago. There must be a moderate or high risk of recurrence; neoadjuvant therapy is not required. Patients may have received anti-hormone therapy for a maximum of 12 weeks.

Facts

  1. What is the disease: -positive, -negative breast cancer
  2. Cancer characteristics: First phase of treatment, including surgery, completed; early stage (stages 0–2); maximum of 12 weeks of anti-hormonal therapy; moderate or high risk of
  3. What the study is investigating: The efficacy and safety of (a next-generation oral ) compared to standard anti-hormonal therapy ( or ) as adjuvant treatment
  4. Study objective: To evaluate the efficacy and safety of camizestrant
  5. Study duration: 7 years of treatment and up to 14 years of
  6. Study characteristics: , open-label, two-arm Phase 3 study, multicenter

Trial sites

30 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Aachen AöR

    Pauwelsstrasse 30, 52074 Aachen

    Active, not recruiting
  • Klinikum Darmstadt GmbH

    Grafenstrasse 9, 64283 Darmstadt

    Status unknown
  • Städtisches Klinikum Dessau

    Auenweg 38, 06847 Dessau-Rosslau

    Status unknown
  • Onkozentrum Dresden

    Leipziger Strasse 118, 01127 Dresden

    Status unknown
  • Kostara Gyn. Oncology Clinic Research UG (haftungsbeschraenkt)

    Luise-Rainer-Strasse 6-10, 40235 Duesseldorf

    Status unknown
  • KEM I Evang. Kliniken Essen-Mitte gGmbH

    Essen

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.